MarketInOut Stock Screener Log In | Sign Up
 

Immunovant Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Immunovant Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,010.68 mln
Float84.82 mln
Earnings Date11/09/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

31 / 100
Underperforming

Pre-Tax Margin

-7,596%
Severely loss-making

ROE

-72.69
Deeply negative

ROA

-65.53
Deeply negative

Business Description

Immunovant is a New York-based medical research company focused on developing new treatments for autoimmune conditions, where the immune system mistakenly attacks the body. The company is working on two experimental drugs targeting a range of serious diseases, including rheumatoid arthritis, lupus, and several rare neurological and eye conditions. Founded in 2018, Immunovant operates as part of Roivant Sciences.

Key Fundamentals

EPS-2.82
ROE-72.69
RPS0.03
ROIC-2,927
ROA-65.53
EBITDA, mln-539
EV / EBITDA-11.42
EV / EBIT-11.42
Revenue, mln7.09

Quote Details

Last 28.41
Change -0.69 (-2.37%)
Open 28.93
Volume 641,148
Turnover 18,215,014
Average Volume 1,438,909

Financial Ratios

Pre-Tax Profit Margin-7,596
Leverage Ratio1.16
Current Ratio7.27
Price / Book9.46
Price / Tangible Book9.46
Price / Sales847

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio11.32
Short % of Float18.74

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.29% 90 / 100   
1 Month -16.44% 21 / 100   
2 Months -28.83% 17 / 100   
6 Months -0.59% 53 / 100   
1 Year 50.32% 92 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog